REPROS THERAPEUTICS INC.
2408 Timberloch Place, Suite B-7
The Woodlands, Texas 77380
August 1, 2017
VIA EDGAR TRANSMISSION
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Attention: | Jeffrey Gabor, Division of Corporation Finance, Office of Healthcare & Insurance |
| Re: | Repros Therapeutics Inc. |
Registration Statement on Form S-3
Filed July 24, 2017
File No. 333-219428
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Repros Therapeutics Inc. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-219428), so that such registration statement may become effective at 4:00 p.m. (Washington, D.C. time) on August 4, 2017, or as soon as practicable thereafter.
| REPROS THERAPEUTICS INC. | |||
| By: | /s/ Kathi Anderson | ||
| Name: | Kathi Anderson | ||
| Title: | Chief Financial Officer | ||
